Entera Bio Ltd. (ENTX) NASDAQ
1.25
-0.02(-1.57%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Entera Bio Ltd.
Address
Kiryat Hadassah Minrav Building
Jerusalem, 9112002
Israel
Phone
972 2 532 7151
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
June 28, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Miranda J. Toledano | Chief Executive Officer & Director | 562,000 | 1977 |
| Dana Yaacov-Garbeli | Chief Financial Officer | 226,000 | 1983 |
| Gregory Burshtein | Chief of Research & Development | 254,000 | 1977 |
| Hillel Galitzer | Chief Operating Officer | 307,000 | 1978 |
| Rachel Wagman | Chief Clinical Advisor | 0 | N/A |
| Cherin Smith | Executive Vice President & Head of Clinical Operations | 0 | N/A |
| Constantin Itin | Head of Biopharmaceutics & Bioanalytics | 0 | N/A |
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
